Data gathered: April 2
AI Stock Analysis - Regeneron (REGN)
Analysis generated January 27, 2025. Powered by Chat GPT.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company focused on the discovery, development, manufacturing, and commercialization of pharmaceuticals. Regeneron is well-known for its innovative approach to drug development, leveraging genetics to identify new and effective therapies for various diseases. The company has a robust pipeline of drugs and collaborative relationships with other industry giants.
Stock Alerts - Regeneron (REGN)
 |
Regeneron | March 28 Rob Bresnahan (member of U.S. congress) is selling shares |
|
Regeneron | March 13 Julie Johnson (member of U.S. congress) is selling shares |
|
Regeneron | March 10 Price is up by 5.2% in the last 24h. |
|
Regeneron | February 27 Employee Rating is down by 2.5% over the last month. |
Alternative Data for Regeneron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 317 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 274,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 63 | Sign up | Sign up | Sign up |
| Patents | 1,391 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2,304 | Sign up | Sign up | Sign up |
| Facebook Followers | 18,223 | Sign up | Sign up | Sign up |
| Instagram Followers | 14,567 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 38 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,197 | Sign up | Sign up | Sign up |
| Twitter Followers | 32,951 | Sign up | Sign up | Sign up |
| Twitter Mentions | 73 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 58 | Sign up | Sign up | Sign up |
| Lobbying Cost | $133,000 | Sign up | Sign up | Sign up |
| Business Outlook | 75 | Sign up | Sign up | Sign up |
| Linkedin Employees | 15,748 | Sign up | Sign up | Sign up |
About Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
| Price | $617.00 |
| Target Price | Sign up |
| Volume | 1,060,000 |
| Market Cap | $69.7B |
| Year Range | $617 - $1200.24 |
| Dividend Yield | 0.56% |
| PE Ratio | 16.53 |
| Analyst Rating | 73% buy |
| Earnings Date | April 29 '25 |
| Industry | Biotechnology |
In the news
 |
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron PharmaceuticalsApril 1 - Yahoo |
 |
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $973.13 Consensus Price Target from AnalystsMarch 31 - ETF Daily News |
|
Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week LowsMarch 29 - Yahoo |
 |
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPDMarch 29 - Indianpharmapost.com |
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025March 25 - GlobeNewswire |
|
|
Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street AnalystsMarch 25 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 3.79B | 1.06B | 2.73B | 918M | 990M | 12.070 |
| Q3 '24 | 3.72B | 714M | 3.01B | 1.34B | 1.63B | 12.460 |
| Q2 '24 | 3.55B | 759M | 2.79B | 1.43B | 1.21B | 11.560 |
| Q1 '24 | 3.13B | 689M | 2.44B | 722M | 873M | 9.550 |
| Q4 '23 | 3.42B | 947M | 2.47B | 1.16B | 1.12B | 11.860 |
Insider Transactions View All
| McCourt Marion filed to sell 12,931 shares at $844.6. November 5 '24 |
| RYAN ARTHUR F filed to sell 17,678 shares at $1042.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,582 shares at $1059.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,586 shares at $1056.7. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,592 shares at $1053.5. October 3 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Mar 28, 25 | Sell | $1K - $15K |
| Julie Johnson |
Mar 13, 25 | Sell | $1K - $15K |
| Julie Johnson |
Feb 13, 25 | Buy | $1K - $15K |
Read more about Regeneron (REGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Regeneron?
The Market Cap of Regeneron is $69.7B.
What is Regeneron's PE Ratio?
As of today, Regeneron's PE (Price to Earnings) ratio is 16.53.
When does Regeneron report earnings?
Regeneron will report its next earnings on April 29 '25.
What is the current stock price of Regeneron?
Currently, the price of one share of Regeneron stock is $617.00.
How can I analyze the REGN stock price chart for investment decisions?
The REGN stock price chart above provides a comprehensive visual representation of Regeneron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regeneron shares. Our platform offers an up-to-date REGN stock price chart, along with technical data analysis and alternative data insights.
Does REGN offer dividends to its shareholders?
Yes, Regeneron (REGN) offers dividends to its shareholders, with a dividend yield of 0.56%. This dividend yield represents Regeneron's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Regeneron in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Regeneron?
Some of the similar stocks of Regeneron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.